Stable isotope tracer dilution for quantifying very low-density lipoprotein-triacylglycerol kinetics in man
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Stable isotope tracer dilution for quantifying very low-density lipoprotein-triacylglycerol kinetics in man. / Sidossis, Labros S; Magkos, Faidon; Mittendorfer, Bettina; Wolfe, Robert R.
In: Clinical Nutrition, Vol. 23, No. 4, 2004, p. 457-466.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Stable isotope tracer dilution for quantifying very low-density lipoprotein-triacylglycerol kinetics in man
AU - Sidossis, Labros S
AU - Magkos, Faidon
AU - Mittendorfer, Bettina
AU - Wolfe, Robert R
N1 - Copyright 2003 Elsevier Ltd.
PY - 2004
Y1 - 2004
N2 - Background & aim: A number of approaches have been employed in the past to measure very low-density lipoprotein (VLDL) triacylglycerol (TG) kinetics in humans in vivo, varying in the selection of tracer and mode of administration. All, however, make use of labeled TG precursors and more or less complicated mathematical models to derive the kinetic parameters of interest. The aim of the present study was to develop a conceptually straightforward method, based on the traditional tracer infusion technique, for quantifying VLDL-TG production rates in man using stable isotopes.Method: Our approach involves ingestion of [U-13C3]glycerol to endogenously label the glycerol in VLDL-TG, plasmapheresis, isolation of the newly 13C-labeled VLDL from plasma, and administration within the next 2-3 days via a primed constant autologous reinfusion. This procedure produces enough tracer for a priming dose plus 2-3 h of infusion. In the physiological conditions examined (basal and hyperglycemic states, fat- and carbohydrate-rich diets), with almost 3-fold ranging VLDL-TG pool sizes, a steady state in plasma VLDL-TG glycerol tracer-to-tracee ratio was readily achieved within 2 h. Consequently, calculations are made according to the isotope dilution principle, thus avoiding assumptions implicit in more complicated models.Conclusion: The stable isotope VLDL-TG tracer dilution method offers an alternative and reliable tool for the determination of endogenous VLDL-TG kinetics in man under a variety of metabolic states.
AB - Background & aim: A number of approaches have been employed in the past to measure very low-density lipoprotein (VLDL) triacylglycerol (TG) kinetics in humans in vivo, varying in the selection of tracer and mode of administration. All, however, make use of labeled TG precursors and more or less complicated mathematical models to derive the kinetic parameters of interest. The aim of the present study was to develop a conceptually straightforward method, based on the traditional tracer infusion technique, for quantifying VLDL-TG production rates in man using stable isotopes.Method: Our approach involves ingestion of [U-13C3]glycerol to endogenously label the glycerol in VLDL-TG, plasmapheresis, isolation of the newly 13C-labeled VLDL from plasma, and administration within the next 2-3 days via a primed constant autologous reinfusion. This procedure produces enough tracer for a priming dose plus 2-3 h of infusion. In the physiological conditions examined (basal and hyperglycemic states, fat- and carbohydrate-rich diets), with almost 3-fold ranging VLDL-TG pool sizes, a steady state in plasma VLDL-TG glycerol tracer-to-tracee ratio was readily achieved within 2 h. Consequently, calculations are made according to the isotope dilution principle, thus avoiding assumptions implicit in more complicated models.Conclusion: The stable isotope VLDL-TG tracer dilution method offers an alternative and reliable tool for the determination of endogenous VLDL-TG kinetics in man under a variety of metabolic states.
KW - Adult
KW - Carbon Isotopes
KW - Glycerol/administration & dosage
KW - Humans
KW - Infusions, Intravenous
KW - Isotope Labeling/methods
KW - Lipoproteins, VLDL/metabolism
KW - Male
KW - Postprandial Period
KW - Triglycerides/metabolism
U2 - 10.1016/j.clnu.2003.11.006
DO - 10.1016/j.clnu.2003.11.006
M3 - Journal article
C2 - 15297080
VL - 23
SP - 457
EP - 466
JO - Clinical Nutrition
JF - Clinical Nutrition
SN - 0261-5614
IS - 4
ER -
ID: 297239533